Elicio Therapeutics, Inc. (NASDAQ:ELTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Posted by on Aug 24th, 2026

Elicio Therapeutics, Inc. (NASDAQ:ELTX – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $19.75.

Several brokerages recently commented on ELTX. Weiss Ratings lowered shares of Elicio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 29th. JonesTrading downgraded Elicio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 16th. LADENBURG THALM/SH SH assumed coverage on Elicio Therapeutics in a research report on Thursday, June 18th. They issued a “buy” rating and a $12.00 target price on the stock. Rodman & Renshaw reiterated a “buy” rating on shares of Elicio Therapeutics in a report on Monday, June 15th. Finally, B. Riley Financial initiated coverage on Elicio Therapeutics in a research report on Wednesday, June 10th. They set a “buy” rating and a $27.00 price target for the company.

Check Out Our Latest Analysis on ELTX

Institutional Trading of Elicio Therapeutics

A number of institutional investors have recently modified their holdings of ELTX. Bank of America Corp DE increased its position in Elicio Therapeutics by 186.8% during the 3rd quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock worth $39,000 after purchasing an additional 2,335 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Elicio Therapeutics during the second quarter valued at approximately $46,000. Deutsche Bank AG purchased a new stake in Elicio Therapeutics during the second quarter worth approximately $49,000. Bank of New York Mellon Corp purchased a new stake in Elicio Therapeutics during the second quarter worth approximately $62,000. Finally, Summit Financial LLC acquired a new stake in shares of Elicio Therapeutics in the fourth quarter worth $80,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Elicio Therapeutics Trading Down 0.7%

NASDAQ:ELTX traded down $0.02 during mid-day trading on Monday, reaching $3.02. The company’s stock had a trading volume of 31,588 shares, compared to its average volume of 745,255. The company’s fifty day simple moving average is $3.35 and its two-hundred day simple moving average is $8.26. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.77 and a quick ratio of 2.77. Elicio Therapeutics has a twelve month low of $2.66 and a twelve month high of $16.00. The stock has a market cap of $79.37 million, a P/E ratio of -1.39 and a beta of 1.30.

Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.11. On average, equities analysts predict that Elicio Therapeutics will post -2.1 EPS for the current year.

Elicio Therapeutics Company Profile

(Get Free Report)

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Featured Stories

Analyst Recommendations for Elicio Therapeutics (NASDAQ:ELTX)

Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.